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Since 1996, vancomycin-intermediate Staphylococcus aureus (VISA; vancomycin minimum inhibitory concentration [MIC] =8-16 ug/mL) has been identified in Europe, Asia, and the United States. The emergence of reduced vancomycin susceptibility in S aureus increases the possibility that some strains will become fully resistant and that available antimicrobial agents will become ineffective for treating infections caused by such strains. The CDC recently reported the fourth case of confirmed VISA from a patient in the United States.
The case was a 63-year-old woman with methicillin-resistant Staphylococcus aureus bacteremia (MIC<1 pg/mL) who was transferred from a long-term-care facility to an Illinois hospital (hospital A) in April 1999. The patient had a history of frequent hospitalizations for complications of hemodialysis-dependent, endstage renal disease and intravascular access, including two failed arteriovenous grafts, multiple central venous catheter-associated infections, and intermittent receipt of vancomycin therapy through June 1998. Thirteen days after hospital admission and 25 days after initiating vancomycin therapy (median vancomycin serum concentration=12.7 ug/mL; range, 12.1 ug/mL-20.9 ug/mL), a culture from her blood grew S aureus with an MIC of 4 ug/mL; the blood culture was tested using the Vitek system (bioMerieux, Hazelwood, MO). Three subsequent blood specimens drawn within the next 3 days grew S aureus with MICs of 8 ug/mL on confirmatory testing. The isolates, identical by pulsed-field gel electrophoresis, were resistant to penicillin, oxacillin, clindamycin, erythromycin, ciprofloxacin, and rifampin but susceptible to trimethoprim-sulfamethoxazole, and tetracycline, gentamicin and had intermediate susceptibility to chloramphenicol. No VISA strains were recovered from other body sites. An echocardiogram demonstrated a mitral valve vegetation, but the patient declined surgical intervention. Despite treatment with intravenous vancomycin, rifampin, and tobramycin, the patient died 10 days after the first VISA blood specimen was drawn; the cause of death was endocarditis.
The VISA isolate was interpreted as "susceptible" at 4 ug/mL by the Vitek system. Susceptibility results were confirmed by the CDC. 
